DB107 and radiation therapy for high-grade glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a newly diagnosed high-grade glioma that hasn't been treated before with surgery, radiation, or chemotherapy.
- Your surgeon believes at least 80% of the tumor can be safely removed.
- You are willing to provide a blood sample for genetic testing.
- You have no active infections, bleeding disorders, or HIV, and you aren't pregnant or breastfeeding.
- Your liver, kidney, and blood cell counts are within safe levels for surgery and treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
This trial tests whether the study drug WP1066 combined with radiation can better control newly diagnosed glioblastoma, a fast-growing brain tumor. It also aims to check safety and how well tumors respond by using brain scans.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests a new approach to radiation therapy for newly diagnosed, aggressive brain tumors. It uses an MRI-guided machine (MR-linac) to deliver radiation more precisely, while studying how to make treatment safer and more effective.
This trial tests a new way of giving radiation therapy (pulsed) compared to standard radiation for people with a specific type of glioblastoma (IDH wildtype, MGMT unmethylated). The goal is to see if the pulsed approach helps with thinking and memory while still treating the tumor.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.